Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00041483
Status:
COMPLETED
Last Update Posted:
2014-07-01
First Post:
2002-07-09
Brief Title:
Phase 3 Study to Evaluate Anecortave Acetate vs Visudyne for the Treatment of the Wet Form of AMD
Sponsor:
Alcon Research
Organization:
Alcon Research
Study Overview
Official Title:
Phase 3 Study to Evaluate Anecortave Acetate vs Visudyne for the Treatment of the Wet Form of AMD
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy PDT with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None